Our Lady of Fatima University

120 McArthur Highway Valenzuela City

Evidence-Based Practice for “ Gastrointestinal Disorder”

In Partial Fulfillment of the Requirements in NCMB316

Submitted by:
Bartolome, Janize Khate S.

Submitted to:
Potenciana A. Maroma, RN, MAN, Ph.D
 Abstract

Evidence-based management of gastrointestinal (GI) illnesses is the focus of this special issue of
Gastroenterology Report. Twenty years ago, many of the diagnostic procedures and treatments
that gastroenterologists use today were entirely unavailable. Our industry is one that is always
innovating and changing.

With an emphasis on evidence to support best practices and to achieve the greatest outcomes for
our patients, this issue involves authoritative reviews on how to manage a wide range of
conditions that affect the GI and biliary tracts using both established and emerging technologies.
For instance, much has changed in terms of our diagnostic accuracy for celiac disease. Serum
IgA antibody against tissue transglutaminase, the go-to diagnostic test, was developed in the last
20 years, revolutionizing the sector (IgA-tTG). Anti-endomysial antibody, the previous "gold
standard," was supplanted by this assay (EMA). IgA-tTG, which has a specificity and sensitivity
above 95%, is the screening test of choice for diagnosing celiac disease in practice, as detailed by
Castillo et al. in this issue. Significantly, celiac disease affects close to 1% of the population in
Europe and North America, but many individuals go undetected because they don't show the
typical signs or symptoms, including persistent diarrhea, weight loss, malabsorption, or anemia.
Refractory gastroesophageal reflux disease (GERD), which persists despite proper treatment
with proton pump inhibitors in patients with reflux esophagitis, is becoming more widely
recognized (PPIs). A logical and useful strategy for improving the management of these patients
is laid out by Subramanian et al. Some people respond well to increasing their PPI dosage to
twice daily or switching to a different kind of PPI. Referrals to consider surgical options may be
helpful for people who are truly refractory. Newer endoscopic treatments for refractory GERD
are also covered.
References:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324873/

Library Transaction: